Balzer Lukas, Pennino Davide, Blank Simon, Seismann Henning, Darsow Ulf, Schnedler Mathias, McIntyre Mareike, Ollert Markus W, Durham Stephen R, Spillner Edzard, Ring Johannes, Cifuentes Liliana
Department of Dermatology and Allergy, Biederstein, Technische Universität München, Munich, Germany.
ZAUM - Center of Allergy and Environment (ZAUM), Technische Universität and Helmholtz Center Munich, Munich, Germany.
PLoS One. 2014 Oct 17;9(10):e108619. doi: 10.1371/journal.pone.0108619. eCollection 2014.
Skin testing can expose allergic subjects to potential systemic reactions, sensitization against unrelated proteins, and increased risk of future sting reactions. Therefore the continuous improvement of in vitro diagnostic methods is desirable. Recombinant allergens have been shown to improve the sensitivity of specific IgE (sIgE) detection in vitro whilst no data is available regarding their application and reliability in basophil activation test (BAT). Here we aimed to compare the specificity and sensitivity of recombinant allergens Ves v 1, Ves v 2, Ves v 3 and Ves v 5 in both specific IgE (sIgE) detection in vitro and basophil activation test.
sIgE detection by ELISA or ImmunoCAP and BAT towards the panel of recombinant allergens Ves v 1, Ves v 2, Ves v 3 and Ves v 5 were performed in 43 wasp venom allergic patients with a history of anaphylactic reaction and sIgE seropositivity, as well as 17 controls defined as subjects with a history of repetitive wasp stings but absence of any allergic symptom.
The BAT performed with the recombinant allergens Ves v 1, Ves v 2, Ves v 3 and Ves v 5 markedly improved the specificity of diagnosis in wasp venom allergic subjects when compared to the respective sIgE detection in serum.
BAT performed with the recombinant allergens Ves v 5, Ves v 3 and Ves v 1 provides an emerging highly specific in vitro method for the detection of wasp venom allergy, compared to the sIgE detection. Recombinant allergens applied to BAT represent a step forward in developing reliable in vitro tests for specific diagnosis of allergy.
皮肤试验可能使过敏受试者面临潜在的全身反应、对无关蛋白质的致敏以及未来蜇伤反应风险增加。因此,体外诊断方法的持续改进是可取的。重组变应原已被证明可提高体外特异性IgE(sIgE)检测的灵敏度,而关于其在嗜碱性粒细胞活化试验(BAT)中的应用和可靠性尚无数据。在此,我们旨在比较重组变应原Ves v 1、Ves v 2、Ves v 3和Ves v 5在体外sIgE检测和嗜碱性粒细胞活化试验中的特异性和灵敏度。
对43例有过敏反应病史且sIgE血清学阳性的黄蜂毒液过敏患者以及17例定义为有反复黄蜂蜇伤史但无任何过敏症状的对照者,进行ELISA或免疫捕获法检测sIgE以及针对重组变应原Ves v 1、Ves v 2、Ves v 3和Ves v 5的BAT。
与血清中相应的sIgE检测相比,用重组变应原Ves v 1、Ves v 2、Ves v 3和Ves v 5进行的BAT显著提高了黄蜂毒液过敏受试者诊断的特异性。
与sIgE检测相比,用重组变应原Ves v 5、Ves v 3和Ves v 1进行的BAT为黄蜂毒液过敏检测提供了一种新兴的高特异性体外方法。应用于BAT的重组变应原是开发可靠的体外过敏特异性诊断试验的一个进步。